The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | CLL highlights from ASH: the Phase III AMPLIFY trial
Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses his highlights in chronic lymphocytic leukemia (CLL) from ASH 2024, highlighting the Phase III AMPLIFY study (NCT03836261). This study is investigating the combination of acalabrutinib and venetoclax, as well as the addition of obinutuzumab to this doublet. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Merck: Consultancy; MEI Pharma: Research Funding; AbbVie: Consultancy, Research Funding; Eli Lilly: Consultancy; AstraZeneca: Consultancy, Research Funding; BeiGene: Consultancy; Ascentage Pharma: Consultancy, Research Funding; TG Therapeutics: Consultancy, Research Funding; Surface Technology: Research Funding; Adaptive Biosciences: Consultancy; Janssen: Consultancy; Genmab: Consultancy; BMS: Consultancy; Novartis: Research Funding; Genentech: Consultancy, Research Funding.
